Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 20374 SENECA MEADOWS PARKWAY GERMANTOWN MD 20876 |
Tel: | N/A |
Website: | https://precigen.com |
IR: | See website |
Key People | ||
Randal Joe Kirk Executive Chairman of the Board | Helen Sabzevari President, Chief Executive Officer, Director; President of PGEN Therapeutics, Inc. | Harry Thomasian Chief Financial Officer |
Rutul R. Shah Chief Operating Officer | Jeffrey T. Perez Senior Vice President - Intellectual Property Affairs | Donald P. Lehr Chief Legal Officer, Corporate Secretary |
Business Overview |
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company's proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications. |
Financial Overview |
For the fiscal year ended 31 December 2023, Precigen Inc revenues decreased 77% to $6.2M. Net loss before extraordinary items increased 20% to $95.9M. Revenues reflect Biopharmaceuticals segment decrease of 99% to $75K, Exemplar segment decrease of 49% to $6.2M. Higher net loss reflects Impairment of goodwill increase from $482K to $10.4M (expense), Research & Development - Balancing value increase of 3% to $46.4M (expense). |
Employees: | 202 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $298.08M as of Dec 31, 2023 |
Annual revenue (TTM): | $6.23M as of Dec 31, 2023 |
EBITDA (TTM): | -$82.26M as of Dec 31, 2023 |
Net annual income (TTM): | -$95.90M as of Dec 31, 2023 |
Free cash flow (TTM): | -$68.47M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 248,919,096 as of Feb 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |